IDXX

IDEXX Laboratories (IDXX) presents a strong investment case based on its dominant position in the veterinary diagnostics market. The company demonstrated robust financial performance in 2025, with significant revenue and earnings growth driven by its Companion Animal Group. Key growth drivers include a record number of premium instrument placements, expanding its recurring revenue base. The company's strong free cash flow generation and shareholder returns through buybacks further enhance its appeal. Future growth is expected from innovation in platforms like inVue Dx and CancerDx.